Axon Enterprise (NASDAQ:AXON) Given New $674.00 Price Target at Piper Sandler

Axon Enterprise (NASDAQ:AXON) had its price target cut by stock analysts at Piper Sandler from $690.00 to $674.00 in a report released on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Piper Sandler’s price target indicates a potential upside of 63.56% from the stock’s current price.

A number of other research analysts also recently issued reports on AXON. Citizens Jmp restated a “market outperform” rating and set a $825.00 price target on shares of Axon Enterprise in a report on Monday, April 13th. Weiss Ratings cut Axon Enterprise from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, April 10th. UBS Group decreased their target price on Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. TD Cowen reduced their price objective on shares of Axon Enterprise from $950.00 to $825.00 and set a “buy” rating on the stock in a research report on Wednesday, April 8th. Finally, The Goldman Sachs Group dropped their target price on shares of Axon Enterprise from $720.00 to $625.00 and set a “buy” rating for the company in a research report on Wednesday, April 8th. Sixteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $748.63.

Axon Enterprise Trading Up 6.8%

NASDAQ:AXON traded up $26.23 during midday trading on Thursday, reaching $412.09. 300,415 shares of the stock traded hands, compared to its average volume of 1,033,037. The stock has a market capitalization of $33.20 billion, a P/E ratio of 274.44, a PEG ratio of 8.12 and a beta of 1.44. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.29 and a current ratio of 2.53. The company has a fifty day moving average of $452.24 and a 200 day moving average of $529.24. Axon Enterprise has a 12 month low of $339.01 and a 12 month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.55. The firm had revenue of $796.72 million for the quarter, compared to analysts’ expectations of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The company’s revenue for the quarter was up 38.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.08 earnings per share. On average, research analysts predict that Axon Enterprise will post 1.41 EPS for the current year.

Insiders Place Their Bets

In other news, insider Isaiah Fields sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $535.01, for a total value of $1,070,020.00. Following the transaction, the insider owned 55,588 shares in the company, valued at approximately $29,740,135.88. This represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jeri Williams sold 157 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $490.00, for a total transaction of $76,930.00. Following the sale, the director owned 1,159 shares in the company, valued at approximately $567,910. The trade was a 11.93% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 13,855 shares of company stock valued at $7,109,828. 4.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Axon Enterprise

A number of hedge funds have recently bought and sold shares of the business. Vicus Capital lifted its stake in Axon Enterprise by 3.7% during the 3rd quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 14 shares during the period. Evergreen Capital Management LLC raised its holdings in shares of Axon Enterprise by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 15 shares during the last quarter. NorthCrest Asset Manangement LLC raised its holdings in shares of Axon Enterprise by 5.4% during the third quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 16 shares during the last quarter. WPG Advisers LLC lifted its position in Axon Enterprise by 9.8% during the third quarter. WPG Advisers LLC now owns 190 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 17 shares during the period. Finally, Monte Financial Group LLC lifted its position in Axon Enterprise by 5.5% during the third quarter. Monte Financial Group LLC now owns 325 shares of the biotechnology company’s stock valued at $233,000 after purchasing an additional 17 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Key Headlines Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Company raised full?year revenue growth and cited AI product revenue up ~700% year?over?year — management said this helped drive its ninth consecutive quarter of 30%+ revenue growth, a big catalyst for forward expectations. Axon Raises Guidance With AI Revenue Up 700%
• Positive Sentiment: Q1 revenue beat the top?line consensus — $807m, +34% Y/Y — with software & services up ~35% and counter?drone sales rising over 300%; management raised FY revenue growth to ~30–32% and reiterated strong cash?flow guidance. Axon reports Q1 2026 revenue of $807 million, up 34% year over year
• Positive Sentiment: Analyst support remains — Needham reiterated a Buy and kept a $600 price target, signaling continued confidence in Axon’s growth runway and valuation upside if execution continues. Axon Maintained at Buy as Strong Growth Outlook Supports Unchanged $600 Price Target
• Neutral Sentiment: Bottom?line reception is mixed depending on the benchmark — Axon reported non?GAAP EPS roughly in line with some outlets (or a penny beat) but missed a few other estimates; investors are parsing margin dynamics and one?time items from recurring software momentum. Compared to Estimates, Axon (AXON) Q1 Earnings: A Look at Key Metrics
• Negative Sentiment: Despite top?line strength, some headlines noted shares slipped in extended trading as investors weighed valuation and the modest EPS/margin beats; AXON’s rich multiples and the stock’s recent year?to?date weakness are being factored into near?term sentiment. Axon Shares Slip Despite Q1 Results Above Expectations

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.